Trial Profile
A Phase Two Randomized, Double-blinded, Placebo-controlled Study Combining Physiological, Radiographic, and Biological Biomarkers to Study the Anti-fibrotic Effect of Pirfenidone in CLAD Post Lung-transplantation
Status:
Discontinued
Phase of Trial:
Phase II
Latest Information Update: 19 Aug 2022
Price :
$35
*
At a glance
- Drugs Pirfenidone (Primary)
- Indications Interstitial lung diseases; Lung transplant rejection
- Focus Therapeutic Use
- Acronyms STOP-CLAD
- 16 Mar 2022 Status changed from recruiting to discontinued.
- 19 Jan 2022 Planned End Date changed from 1 Mar 2022 to 1 Apr 2022.
- 05 Jan 2021 Planned End Date changed from 1 Dec 2020 to 1 Mar 2022.